Bastian Dehmel

Corporate Officer/Principal bei OCULIS HOLDING AG

54 Jahre

Health Technology

Consumer Services

Aktive Positionen von Bastian Dehmel

Unternehmen	Position	Beginn	Ende
OCULIS HOLDING AG	Corporate Officer/Principal	01.01.2022	-

Unternehmen	Position	Beginn	Ende
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Technik-/Wissenschafts-/F&E-Leiter	01.10.2017	01.12.2021
Amgen (Europe) GmbH	Corporate Officer/Principal	01.12.2013	01.07.2017

Freie Universität Berlin

Doctorate Degree

International

Operativ

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Doctorate Degree	1

Sektoral

Health Technology	3
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
OCULIS HOLDING AG	Health Technology

Private Unternehmen	2
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology
Amgen (Europe) GmbH

Private Unternehmen

Health Technology

Amgen (Europe) GmbH